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1. Introduction
Pruritus is a nociceptive sensation transmitted centrally from the periphery by the unmyeli‐
nated, large, slowly conductive C fibers [1]. Pruritus is the dominant symptom of skin disease
and a frequent manifestation of systemic disease. Of all of the systemic disorders, uremia is
certainly the most important cause of pruritus [2]. The association between uremia and
pruritus was first reported more than a century ago. Patients with severe chronic renal failure
may be predisposed to the development of xerosis, hyperpigmentation, uremic roseola,
calcinosis cutis, acquired perforating dermatosis, bullous dermatosis of hemodialysis, half and
half nails and pruritus [3,4]. However, pruritus is often the most difficult to manage [5] and
also related to mortality of end-stage renal disease (ESRD) patients. Aside from kidney
transplantation, which is the only definitive treatment, therapeutic approaches for the
treatment of pruritus have largely been empirical. The main goal of therapy remains to
minimize the severity of pruritus and improve the quality of life, especially among those who
are not transplantation candidates or are waiting for surgery.
Uremic pruritus (UP) may not be associated with the initiation of hemodialysis therapy, or
symptoms may first become apparent with it [6]. A global study reported a 42% prevalence of
moderate or extreme UP, which was strongly associated with sleep disturbance, depression,
impaired quality of life and mortality [7]. Another study noted a higher percentage of pruritus
in patients with more advanced chronic kidney disease (CKD): 18% of stage 3, 26% of stage 4,
42% of stage 5 and 58% of stage 5 CKD on maintenance hemodialysis for 1 month or greater
[8] experienced UP. Once pruritus manifests itself, it often persists [6]. Pruritus can be a
temporary condition lasting only a few months, but more commonly, it affects patients for
more than 1 year. About one quarter of patients suffer from it only during or soon after
hemodialysis, whereas others find this period a time of pruritus symptomatic exacerbation
[9,10]. The intensity of pruritus was described as mild in 22- 52.6%, moderate in 22.6- 40% and
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severe in 8- 40% of patients [10-12]. About half of UP patients suffer from continuous itch,
while the others experience it only occasionally with episodes of exacerbation. UP affects
quality of life because of serious discomfort, anxiety, depression and sleeping disorders,
especially because it is usually worse at night [13]. Pruritus may increase in intensity during
the summer months, possibly due to the rising skin temperature reducing the threshold for
the perception of UP, as occurs in other types of pruritus [14]. For that reason, external heat,
sweat and stress can aggravate UP, and cold or hot showers can alleviate the symptoms [15].
The skin may appear normal or display different types of lesions, mostly related to scratching
(e.g., lichen simplex, prurigo nodularis or keratosis papules) [13].
UP may be localized or generalized. Generalized itching is evident in about half of the patients
[6]. Pruritus in dialysis patients is most commonly localized to the back, followed by the
forearm with an arterio-venous fistula (perhaps due to frequent washing and traumatization
of this region), abdomen, or head [16]. It has been reported that patient age, sex, underlying
renal disease or dialysate solution used for hemodialysis (bicarbonate-based or acetate-based)
have no influence on UP [6,10]. However, using less permeable and less biocompatible dialysis
membranes show higher incidence of pruritus [6,10]. Moreover, patients with longer period
of hemodialysis (> 3 months) may have high tendency to experience UP [13], possibly due to
the accumulation of undefined pruritogenic cytokines or other substances [10].
Different scoring systems were used to quantify the severity of UP in clinical trials. The most
commonly used include the visual analogue score (VAS) [17-19], a 4-point pruritus score [20]
and a comprehensive validated questionnaire that was developed based on a short form of the
McGill pain questionnaire [17,21]. This questionnaire was found to be reliable and provided
valid data on the sensory, affective and overall intensity of UP and may provide a basis for
future cross-cultural studies of itching [17] and for other study-specific scales [22].
Clinical appearance of UP can be observed by secondary changes such as atrophy of adnexal
structures, microangiopathy with necrosis of endothelial cells, changes of sebaceous glands,
lesions or lichen complex chronicus, excoriations and prurigo nodularis [23]. Although
hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) seem to be associated
with a similar incidence of UP [24,25], some have found its incidence with CAPD was 10% [4]
to 14% [26] lower, possibly due to a more effective elimination of possible pruritogenic
substances by the peritoneum than by artificial membranes [27].
Due to the effect of UP which can cause serious discomfort, severe anxiety or even depression
and sleeping disorders, it really affect patients' quality of life. Since sleeping disorders are related
to chronic fatigue, it has strong influence on mental and physical health of patients [15]. Recently,
studies demonstrated an association between UP and an increased risk of mortality [7,19].
2. Pathophysiology
The pathophysiology for this condition is not well understood. Known risk factors that
predispose patients to UP are male gender [19], although some studies showed a higher
prevalence in females [22,28], high levels of blood urea nitrogen and elevated calcium,
phosphorus and β2-microglobulin [22,29]. Other contributing factors include hypervitaminosis
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A [20], high aluminum levels [30], anemia, erythropoietin insufficiency, elevated ferritin, low
transferrin, low albumin, peripheral neuropathy [31] and secondary hyperparathyroidism
with elevated divalent ions such as calcium, phosphate and magnesium ions [22]. Xerosis,
which is very frequent in uremic patients as a result of a decrease in sweat volume as well as
atrophy of the sebaceous glands and dehydration of the stratum corneum, may indeed play a
role in UP.
It is hypothesized that UP is caused by the metabolic disequilibrium of CKD [32]. Some studies
mentioned that it involves cutaneous nerve proliferation, pruritogenic cytokines or other
chemicals, mast cell proliferation and secondary hyperparathyroidism. [5] Others propose that
a poorly dialyzable substance is responsible for UP due to its systemic accumulation but that
this resolves with renal transplantation [32]. UP has also been proposed to be a manifestation
of multisystem dysfunction that is comorbid with renal failure. Proinflammatory mediators
such as T-helper (Th)-1 cytokine and interleukin (IL)-2 may play a role in pruritus. Hypercal‐
cemia and hyperphosphatemia with secondary deposition of calcium phosphate crystals in
the skin may also contribute to itch [32]. Some biochemical parameters have been reported to
be associated with the development of UP including magnesium [33], intact-parathyroid
hormone (iPTH) [34], phosphate [33] and calcium [35]. While uremia may cause pruritus, other
etiologies of pruritus must also be ruled out. Patients must be evaluated for endocrine
disorders, atopic dermatitis, infestations, psychiatric disorders (e.g., delusions parasitosis),
contact dermatitis and allergic reactions to the dialysate [23].
In UP, the stimulation of free nerve endings or dermal itch receptors generate impulses via C-
fibers to the spinal cord and further to thalamus and finally reach cerebrum [36]. It is believed
that substance P, which is a type of neurotransmitter, is a key to transmit the sensation of itch [3].
The physical appearances of skin in patients with chronic renal failure are totally difference
from healthy people. Microangiopathy, thickening of basement membrane, epidermal atrophy
or atrophy of sebaceous glands are normally found in hemodialysis patient [37,38,39]. Due to
the lower levels of fat and water content on stratum corneum of skin with chronic kidney
diseases, pruritus is normally found [40]. Reduction of sweat is another factor related to UP
since the amount of electrolytes, lactate, urea, protein, lipids and amino acid elimination are
normally decreased [40]. There is a positive correlation between xerosis and pruritus [11,25],
but no correlation between cutaneous water content or transepidermal water loss and pruritus
has been found [41,42]. However, the stratum corneum layers on the skin of dialysis patients
are significantly less hydration compared to healthy skin [43].
There are several reports indicated that serum levels of divalent ions such as magnesium,
calcium, aluminum and phosphate are related to UP [3,10,40,44]. Magnesium can stimulate
neuron or activate histamine releasing from mast cells [45] while calcium and phosphate can
induce itch receptors and cause metastatic cutaneous calcification [10,30]. An elevated serum
aluminum concentration in chronic hemodialysis patients with UP was also reported as a
possible etiology [30].
Secondary hyperparathyroidism has been proposed as a possible cause of UP, and normally,
end-stage renal disease (ESRD) patients develop secondary hyperparathyroidism [3,46].
However, UP is relieved after parathyroidectomy [46]. Although hyperparathyroidism in UP
is frequently associated with pruritus [47], a positive correlation was not confirmed [3]. Intact
Uremic Pruritus; Its Prevalence, Pathophysiology and Management
http://dx.doi.org/10.5772/59352
21
parathyroid hormone is not related to UP while mid-region parathyroid hormone (m-PTH)
shows some correlation [6]. In patients with UP, the large amounts of inactive carboxy-terminal
metabolites of parathyroid hormone is normally found in serum [6].
Mast cell accumulation and degranulation may play a role in UP [10,48,49]. Parathyroid
hormone is known to stimulate mast cell production and accumulation in various organs [49].
Some studies have shown an increased number of cutaneous mast cells in uremic patients
compared with healthy subjects [10,38], but very few reports show the correlation between
mast cells and pruritus [47,50]. Very numerous, degranulated mast cells with diffusely
distribution within dermis are normally found in patients with UP while mast cells in healthy
subjects are mainly localized and intact in the upper dermis [10,51].
Mediators of inflammation may also be important. Histamine, a well-known mediator of
pruritus in dermatologic disease, is elevated in the plasma of patients with ESRD as a result
of histamine retention in renal insufficiency [52]. Histamine is released from mast cells in
response to substance P and is thought to be implicated in UP. The number of mast cells is
increased in patients with CKD, and increased plasma levels of tryptase and histamine have
been reported in patients with severe UP [53]. In addition, prostaglandins are thought to
modulate pruritus by lowering the threshold for histamine-induced pruritus [54]. There is a
correlation between plasma histamine levels and pruritus [52,55]. It is found that histamine
levels in patients with UP is significant higher compared to nonpruritic subjects [52,55] but
specific differences in plasma histamine levels in subjects with and without UP cannot be found
[26,56]. Since antihistamine has been widely used but ineffective for the treatment of UP,
histamine should not have a significant role for this symptom [57].
It is possible that there are unknown pruritogenic cytokines produced by activated cells in
some itching dermatoses [36]. Nitric oxide was also postulated to have a possible role in the
development of UP [58], as it can be synthesized from cells under inflammatory stimulants
including tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and IL-1β, and it has cytotoxic
effects that can be involved in inflammatory dermatoses. During hemodialysis, several
cytokines, including IL-1, are released following contact between plasma and the dialysis
membrane [59]. IL-1 has been postulated to induce the release of inflammatory and potentially
pruritogenic substances [6].
The two newest hypotheses that were proposed to explain the underlying pathophysiological
mechanisms of UP are the immune hypothesis and the opioid hypothesis [22]. The immune
hypothesis considers UP to be an inflammatory systemic disease [21] with over-activation of
CD4+TH1 lymphocytes and overproduction of IL-2, IFN-γ and TNF-α. IL-2 is released during
hemodialysis secondary to the contact of blood and dialysis membranes [60], and it is known
to be pruritogenic when injected into the skin. The increased serum levels of inflammatory
biomarkers such as C-reactive protein and IL-6 confirms the inflammatory nature of the disease
[61]. For the opioid hypothesis, it is well known that opioids play a role in modulating the
sensation of pruritus both centrally and peripherally. Endogenous opioids are known to play
a role in cholestatic prutitus [22], but it was also postulated that they have a role in UP
secondary to the overexpression of opioid µ-receptors in dermal cells and lymphocytes, and
concomitant down-regulation of opioid κ-receptors caused by the increase in serum β-
endorphin to endorphin A ratio that is observed in patients with CKD [62]. Despite all these
mechanisms, the certain pathophysiology of UP remains unknown.
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3. Treatment
Despite high prevalence and life-altering comorbidities, UP remains poorly characterized and
lacks effective treatment [63]. Because the pathophysiological mechanisms of UP are poorly
understood, the treatments have largely been empirical, and no treatment has been shown to
have sufficient efficacy and safety [64]. Moreover, no drugs have been approved by the U.S.
Food and Drug Administration for this problem. Before considering the treatment of UP, an
evaluation should be performed to define whether pruritus in a specific patient is caused by
uremia (which needs adequate dialysis) or is related to dermatologic or systemic disease such
as hyperparathyroidism, hyperphosphatemia and anemia that may require a different approach
[2]. Once the etiology of pruritus has been established, several therapies can potentially be
adopted. Treatments can be classified as topical, physical or systemic applications.
In order to control UP in dialysis patients, several factors need to be monitored such as
improvement of nutritional status, monitoring of calcium and phosphorus levels, optimization
of dialysis efficacy as well as use of biocompatible dialysis membranes [65]. Pruritus found in
CKD may cause from other disorders such as liver diseases (for instance; hepatitis), endocrine
disorders (for instance; Graves' disease, diabetes mellitus and hypothyroidism) and skin
disorders (such as atopic dermatitis, psoriasis, contact dermatitis and urticaria). Pruritus found
in these causes need specific treatments which may differ from standard treatment [53]. A step-
up therapeutic approach for UP in patients with CKD is presented in Figure 1.
a Use of evening primrose oil rich in essential fatty acids (γ-linolenic acid), bath oil that contains polidocanol and cream
that contains natural lipids and endocannabinoids can be attempted if simple emollients fail.
b For intractable UP that does not respond to nalfurafine (5 µg intravenously thrice weekly for 4 weeks), treatment with
short courses of topical tacrolimus ointment (0.1% for 2-6 weeks) or oral thalidomide (100 mg daily for 2-4 weeks) can
be attempted.
*Reprint with permission from publisher (Kuypers, DRJ., Skin problems in chronic kidney disease. Nat. Clin. Pract.
Nephrol. (2009).
Figure 1. Step-up therapeutic approach for UP in a patients with CKD.
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4. Physical Treatments
4.1. Modification of Dialysis Techniques and Mineral Abnormalities
The prevalence of UP declines by using biocompatible dialysis membranes [66]. Hence, the
first approach to improve UP is still to optimize the dialysis efficiency, use biocompatible
dialysis membranes and improve the nutrition status of patients. One study demonstrates that
in a series of 30 cases, a polymethylmethacrylate (PMMA) artificial kidney may be a useful
adjuvant therapy in chronic hemodialysis patients with severe UP, as it may eliminate more
serum cytokines by adsorption than other types of high-flux membranes [67].
Because divalent ions, including magnesium and calcium, may possibly be involved in the
pathogenesis of uremia, using a hemodialysis bath with low calcium and magnesium concen‐
tration [45,68,69] and keeping the calcium × phosphate product less than 55 mg2/dL2 can play
a role in improving the pruritus [35]. However, drastic reduction in dialysate calcium concen‐
tration may possibly aggravate renal osteodystrophy.
4.2. Efficient Dialysis
It is a common experience that pruritus is more frequent in underdialyzed patients and
improves by increasing the efficacy of dialysis. Pruritus patients tend to have higher blood
urea nitrogen and lower Kt/V values [70]. Increasing the Kt/V from a mean of 1.05 to 1.24 in
severely pruritic patients improved their symptoms significantly [70].
4.3. Parathyroidectomy
Patients who experience pruritus together with hypercalcemia and hyperparathyroidism
should be treated by parathyroidectomy [46,71]. However, there is no relation between
parathyroid hormone and UP, parathyroidectomy should not be used as a routine procedure
[2]. It was found that patients with hypocalcemia or serum calcium at the normal limit can still
experience pruritus. It can be concluded that the relationship between serum calcium level and
pruritus is hardly found [72].
4.4. Phototherapy
The role of phototherapy in renal pruritus has been assessed by double-blind trials. Ultraviolet
B (UVB) has been generally, although not uniformly, shown to be therapeutic. The mechanism
of the antipruritic effect of UVB is not completely understood. Among the proposed mecha‐
nisms are inactivation of a circulating pruritogenic substance, formation of a photo-product
that relieves pruritus, alteration of divalent ion content in the skin, suppression of histamine
release as well as deactivation of circulating pruritogenic substances [16] and promotion of
cutaneous nerve degeneration [73,74]. UVB phototherapy is well tolerated aside from occa‐
sional instances of sunburn [75]. The duration of the antipruritic effect of thrice-weekly, total
body UVB phototherapy (8- 10 sessions in total) is variable but can last for several months. In
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1975, Saltzer et al. first described successful treatment with irradiation of UVB (wavelength
280- 315 nm), [76] and the results were confirmed by several studies [32,75,77,78]. The study
also showed that there was no significant difference between remission rates or length of
remission between the intensive, intermediate and prolonged treatment schedule [75,79].
Later, a study by Blachley et al. not only showed the efficacy of UVB treatment in 17 patients
clinically but also showed, by obtaining skin biopsies before and after therapy, a reduction in
skin phosphorus following UVB treatment to values that were comparable with those of
patients with nonpruritic uremia or healthy volunteers [77]. Further investigation has been
performed using narrowband UVB phototherapy, as most of the data on UV radiation have
been predominately derived from studies using broadband UVB [80]. The results showed the
effectiveness of narrowband UVB, as 9 of 15 patients with UP were marked as responders;
however, remission was not prolonged, as 4 of 6 responders who came back for a follow-up
had a recurrence [80,81]. Due to the carcinogenic effect of UVB, ultraviolet A (UVA, wavelength
315- 400 nm), which is safer than UVB, was studied for its efficacy, however, UVA did not
demonstrate any benefit [82]. Narrowband UVB, which is generally accepted to be less
carcinogenic than broadband UVB, should be a better alternative treatment in both efficacy
and safety aspects.
4.5. Acupuncture and Electrical Needle Therapy
Modern medicine tries to explain the efficacy of acupuncture by describing its effects on the
receptors of the nervous system, its action on the endogenous endorphin enkephalin and 5-
hydroxytryptamine (5-HT), or that it can increase the number of leukocytes and strengthen
the defensive mechanisms of the body [83]. Some studies show the benefit of acupuncture for
UP. The fundamental information indicated that pruritus was transmitted by conductive C
fibers, and acupuncture generates impulses that are carried by the smaller, myelinated, and
rapidly conductive beta and delta fibers, all of which reach the spinal cord. There, opiate-like
substances are released that block the slower C fiber impulses [84].
Acupoint injection, at San Yin Jiao (SP6), Xuehai (SP 10), Zusanli (ST 36) and Quchi (LI 11)
acupoints, has been reported to be effective in UP [85]. Using a transcutaneous electrical nerve
stimulation (TENS) acupressure apparatus at those points also showed a benefit in reducing
UP [86]. Duo also reported that an electric needle is effective at two similar points (Quchi and
Zusanli) [87]. Che-yi et al. also reported that acupuncture at the Quchi (LI 11) acupoint, which
is close to the hemodialysis needle puncture site but not too close for acupuncture there to
interfere with hemodialysis, is also effective for relieving UP [1]. However, acupuncture does
not change the level of biochemical parameters associated with the development of UP—
including magnesium, iPTH, phosphate and calcium.
4.6. Thermal Therapy
Hsu et al. investigated the effects on UP of 40 degree Celsius thermal therapy with far-infrared
rays at the Sanyinjiao acupoint for 15 minutes and found a large decrease in pruritus scores in
Uremic Pruritus; Its Prevalence, Pathophysiology and Management
http://dx.doi.org/10.5772/59352
25
the thermal therapy group compared with the non-thermal therapy group, even though there
was no significant differences between groups [88]. The result implied that thermal therapy
may have therapeutic benefits for UP.
4.7. Sauna
Stimulation of the sweat glands with a sauna has shown benefits, perhaps through augmented
excretion of hypothetical pruritogen [89]. However, such treatment may cause major compli‐
cations in fluid balance due to unquantifiable insensible water loss.
5. Topical Treatments
Topical treatment with skin emollient contained high water to hydrate stratum corneum is
considered as a primary therapy for UP in CKD patients. In order to avoid any allergic reaction,
emollients without perfumes or other additives is preferable [43,90].
5.1. Skin Emollients
Because xerosis plays at least an adjuvant role in the development of UP, emollients are a
mainstay in the treatment. It has been suggested by several researchers that the use of
emollients with high water content should be the first-line treatment [91,92]. The benefit of
using emollients to treat dry skin in patients with UP has been reported by Morton et al. and
others [9,43,93]. A pilot study on the use of urea 10% lotion with dexpanthenol, a moisturizer,
showed significant improvement in skin itch [20]. The study by Balaskas et al. of 100 patients
using glycerol and paraffin, showed a 75% improvement in UP and hence quality of life
(p<0.001) [94]. The addition of endocannabinoids to creams containing structured physiolog‐
ical lipids demonstrated good efficacy and tolerance in a clinical study [61,95].
5.2. Sericin Cream
Sericin, a biopolymer with a high molecular weight, is a water-soluble protein that is obtained
from the silkworm (Bombyx mori). Sericin is characterized by the presence of 32% serine, which
is the main amino acid of the natural moisture factor (NMF) in human skin; therefore, sericin
has excellent moisturizing properties that may be helpful for treating hypohidrosis. Sericin
also demonstrates many biological activities and has been widely studied for potential use in
medicines and biomaterials [96-100]. Moreover, sericin can significantly decrease the levels of
the pro-inflammatory cytokines TNF-α and IL-1β in sericin-treated wounds in rats 7 days after
an injury, compared with the levels found in normal saline-soaked wounds and cream base-
treated wounds [101]. As previously mentioned, the immune-inflammatory hypothesis
considers UP a dermatologic manifestation of chronic inflammation and treats the condition
as a possible result of derangements in the immune system that are based on a pro-inflamma‐
tory pattern. Based on this reasoning, sericin was investigated for relieving UP. An in-subject,
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randomized, double-blind, placebo-controlled experimental study was designed to investigate
the effects of sericin cream (concentration 8%) versus the cream base (placebo) applied twice
daily for 6 weeks in reducing the symptoms of UP (itching, dryness and redness) and skin
pigmentation in 47 subjects with stable maintenance hemodialysis [102]. The results showed
that sericin reduces pruritus in patients with UP. The use of sericin cream significantly
increased the level of skin hydration after 6 weeks of treatment compared to baseline and to
the use of the cream base. The use of sericin cream also significantly reduced the level of skin
irritation and pigmentation after 6 weeks of treatment compared to baseline, while use of the
cream base reduced skin pigmentation slightly but not significantly. Patients' quality of life
was also assessed using the Thai version of the KDQOL-SF Version 1.3, and the results showed
a better quality of life in all of the measured domains, including sleep and mood/emotional
distress after the treatment period. When the mean score on the enrollment day was compared
with the mean score on the day after the completion of treatment, significant differences were
found in some domains, including pain, the symptoms/problems list in kidney disease, the
effect of kidney disease on daily life and sleep, the most relevant parameter for itching. The
overall score increased from 60.00 at the time of enrollment to 61.95 after 6 weeks of treatment,
although this difference was not statistically significant. The results of this study suggest that
sericin cream may be a good choice for treating pruritus in hemodialysis patients. Because
sericin is obtained from natural sources that have high biocompatibility, it may cause fewer
allergic reactions and lower resistances compared to other chemical substances.
5.3. Capsaicin
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide), an extract from capsicum or common
pepper plant, can be used as a main ingredient in cream for the treatment of painful disorders
including postherpetic neuralgia, cluster headaches, diabetic neuropathy, osteoarthritis and
phantom limb [103,104]. Capsaicin blocks pain and itching by depleting and preventing the
re-accumulation of substance P from local type C sensory nerve terminals [89,104]. After using
0.025% capsaicin cream for the treatment of UP in long-term dialysis patients, the results
indicated that significant alleviation of pruritus was found with no serious adverse reaction
[105,106]. Although topical capsaicin might be useful for the treatment of localized disease, it
is impractical for large areas or generalized pruritus.
5.4. Tacrolimus
Tacrolimus is an immunomodulator targeting mainly at the T helper cells. It blocks the
differentiation of Th1-type lymphocytes, and therefore, suppresses the production of IL-2. Due
to these mechanisms, it was suggested that it might be beneficial in the treatment of UP. An
observational study of 3 cases of severe UP in patients on peritoneal dialysis indicated a short-
term efficacy of 0.03% tacrolimus ointment over 7 days. However, the use of this agent was
not extended longer because of the potential carcinogenic effect of systemic tacrolimus [107],
which resulted in an FDA black-box warning that was issued in 2006 against the prolonged
topical use of tacrolimus creams and ointments. Nevertheless, some studies failed to demon‐
strate any efficacy of the topical calcineurin inhibitor in patients with UP [108,109].
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6. Systemic Treatments
6.1. Opioid Antagonists
Endogenous opioids have been implicated in the genesis of the pruritus associated with
cholestasis [110,111]. One study demonstrated the effect of naltrexone 50 mg/day for a week
in 15 dialyzed patients with severe UP in a randomized cross-over trial, and the results
indicated that short-term amelioration of UP was found and attributed to the inhibition of
basophil histamine release. Only mild upper gastrointestinal tract symptoms were found to
be the side effects [112]. Opioid antagonists should therefore be considered for patients with
severe and persistent UP [2].
More recently, another perspective was elaborated on regarding the use of a κ-agonist, for κ-
receptor stimulation inhibits µ-receptor effects both peripherally and centrally and hence
might inhibit itching induced by substance P [64]. A meta-analysis approach was used to assess
the efficacy of nalfurafine, which is a κ-agonist, in two randomized placebo-controlled clinical
studies. Nalfurafine was administered intravenously postdialysis over 2-4 weeks, and the
results were encouraging, as improvements in the worst itching, itching intensity and sleep
disturbances were noted in the nalfurafine group, with significant p values [113]. In addition,
the evaluation of adverse events demonstrated that nalfurafine was well tolerated.
6.2. Erythropoietin
De Marchi et al. studied the effect of erythropoietin in dialysis patients with elevated plasma
histamine levels in a placebo-controlled, double-blind, crossover study. They found that
erythropoietin improved UP and decreased plasma histamine concentrations. Further, they
found that it can result in marked improvement of UP and that recurrence of pruritus occurred
after discontinuation of erythropoietin [114]. However, this effect was not related to the change
in hemoglobin levels [115].
6.3. Serotonin Antagonists
Serotonin has been suggested as a possible mediator of cholestasis and UP. One study indicated
that ondansetron, a selective inhibitor of serotonin type 3 receptors, at 4 mg twice a day for
approximately 3 months can significantly reduce the severity of UP in peritoneal dialysis
patients with moderate to severe pruritus [116]. This treatment was well tolerated and showed
no significant side effects. However, the study by Ashmore et al. failed to show any significant
change in the pruritus scores in patients treated with ondansetron in comparison with the
placebo group [117].
6.4. Gabapentin
Gabapentin, a γ-aminobutyric acid analog, is a potent anticonvulsant drug that was has been
clearly demonstrated as effective in the treatment of neuropathic pain, especially diabetic
neuropathy. Considering that neuropathic pain and pruritus share common pathogenic
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mechanisms, gabapentin, which is usually used to treat neuropathic pain, emerged as another
possibility in the arsenal of treatment for severe UP resistant to other therapies [64]. Recent,
limited data suggest that gabapentin is a promising drug in treating UP, given its efficacy and
its safety [13,91,118]. In a randomized, placebo-controlled, double-blind study, 25 patients
were treated with gabapentin versus a placebo for 4 weeks; the treatment was then reversed,
and the mean pruritus score dropped significantly. No patient dropped out due to adverse
events from gabapentin [119]. Regarding its pharmacokinetics, gabapentin is eliminated
primarily through the kidney, and it is removed by hemodialysis. It has a significantly longer
half-life in patients on hemodialysis than in those with normal kidney function, and thus, these
patients need lower doses at less frequent intervals [64]. The recommended dose for hemo‐
dialysis patients is 200- 300 mg after each hemodialysis session, with somnolence, dizziness
and fatigue being the most commonly reported side effects [120].
6.5. Antihistaminic Agents
Despite the fact that histamine might be implicated in the pathogenesis of UP and the dem‐
onstration of elevated histamine levels in patients with ESRD with pruritus [91,121], classical
antihistamines showed very limited efficacy in the treatment of UP [53,54,94,121]. The response
to the administration of antihistaminic agents is marginal, at best [9]. Mast cell stabilizers
including ketotifen, 2-4 mg per day for 8 weeks, [55] and cromolyn sodium [55], however, were
demonstrated to be effective in case series.
6.6. Long Chain Fatty Acids
Abnormalities in the plasma composition of essential fatty acids may be related to the etiology
of pruritus in patients undergoing hemodialysis. After administration of 6 grams of ethyl ester
of either fish oil, olive oil or safflower oil in double-blind study of 25 hemodialysis patients,
the results indicated that pruritus was significantly improved due to the altered plasma fatty
acid profile and increased prostaglandin E2 (PGE2) plasma concentration [122]. Another study
indicated that the improvement in pruritus was due to an increase in PGE1 plasma levels [123]
after administration of γ-linoleic acid-rich evening primrose oil 2 grams per day for 6 weeks.
6.7. Lidocaine and Mexiletine
Parenteral administration of lidocaine, a membrane-stabilizing antiarrhythmic agent, can
relieve pruritus in double-blind study however, significant side effects such as hypotension
and grand mal seizures were found [124]. An oral dosage form of mexiletine, a longer half-life
and less toxicity than lidocaine, was found to be ineffective for the treatment of UP [125].
6.8. Low Protein Diet
Low protein diet has been proposed for the treatment of UP due to the rational of less
accumulation of renally excreted pruritogen [126]. However, low protein diet may lead to
malnutrition which can be dangerous in CKD patients and detoxification showed no benefit
on pruritus [2].
Uremic Pruritus; Its Prevalence, Pathophysiology and Management
http://dx.doi.org/10.5772/59352
29
6.9. Oral Activated Charcoal
With the rationale of adsorbing an unidentified pruritogen, oral activated charcoal at the dose
of 6 grams per day has been used for uremic pruritus. A double-blind crossover trial and a
single-blind study have yielded impressive results [127,128]. This preparation is effective,
inexpensive, and has a favorable side effect profile. However, this treatment has not yet been
accepted and utilized in clinical practice [127,128].
6.10. Cholestyramine
The success of cholestyramine in treating PU is inconsistent. When administered at a dose of
5 grams twice a day, the gastrointestinal side effects are normally found. Moreover, the risk
of acidosis must also be taken into consideration, particularly in patients who are not on
dialysis [128,129].
6.11. Heparin
Patients on hemodialysis may develop pruritus when treated with porcine or bovine heparin.
Pruritus is relieved promptly when another form of heparin is used, implying that these
heparins act as allergens [9]. Paradoxically, administration of heparin at 75- 100 mg twice a
day for 2-3 weeks can improve UP in some dialysis patients [130]. From the mechanism of
action by inhibition of T-lymphocyte heparanase activity which is an important factor for T-
cell migration to target tissues, low molecular weight heparin such as enoxaparin at low dose
is effective in treating pruritus associated with lichen planus [2,131].
6.12. Thalidomide
Thalidomide is a relatively selective inhibitor of TNF-α production. The study indicated that
thalidomide at 100 mg per day administered for 1 week can significantly reduce the intensity
of pruritus by up to 80% in more than half of the subjects, suggesting a potential role for this
agent in the treatment of persistent UP [132].
6.13. Nicergoline
Nicergoline is a dopamine receptor agonist and a partial α-adrenergic blocker related to ergot
alkaloids. A double-blind, placebo-controlled study that investigated the effect of 30 mg per
day by mouth and 5 mg per day intravenously during dialysis, indicated relief of pruritus in
most patients, and the effect lasted for 24- 48 h with improvement persistent in long-term
therapy (30 mg per day) in most patients who responded to the initial treatment [133].
6.14. Nicotinamide
Nicotinamide is the pyridine-3-carboxylic acid amide of niacin, a component of the vitamin B
complex. Namazi et al. suggested 3 mechanisms through which nicotinamide can be effective
in treating UP: the anti-inflammatory effect through the inhibition of the expression of major
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histocompatibility complex (MHC)-II and the production of IL- 12, TNF-α and IL-1; the
inhibition of cyclic adenosine monophosphate (cAMP) phosphodiesterase and stabilization of
mast cells and leukocytes and hence, blocking histamine release; and the increase of the
biosynthesis of ceramides by keratinocytes with the resultant alleviation of xerosis [134]. For
those reasons, nicotinamide could be an effective treatment for UP. However, clinical trials
should be conducted to confirm its efficacy.
7. Conclusion
UP is one of the most common and disabling symptoms for patients with ESRD. It is considered
to be an inflammatory systemic disease rather than a local skin disorder. Biomarkers of
inflammation are increased in patients with UP, and an imbalance of the endogenous opioi‐
dergic system might be involved in the complex pathogenesis of the disease. UP affects up to
90% of patients on dialysis and is associated with a high morbidity and mortality. Given the
complexity of its pathogenesis and the lack of clear evidence regarding the efficacy of more
conservative therapies, the only definitive treatment is kidney transplantation.
Antihistamines, which are the most widely used antipruritic agents, are ineffective for the
treatment of hemodialysis-related pruritus. Safe and effective modalities, and those that
should probably be considered as first-line treatment, are topical emollients. Other physical
therapies and medications should be further investigated due to the inconsistent trial results.
Without definitive treatment of the underlying disease, therapy for hemodialysis-related
pruritus is often palliative at best, aiming to minimize the severity of pruritus and to improve
the quality of life.
The standard of care remains to optimize the dialysis dose and to use biocompatible mem‐
branes, as well as the treatment of mineral abnormalities and anemia. The reasonable course
for treating hemodialysis-related pruritus should be as follows:
a. If the patients can tolerate it, dialysis should achieve a Kt/Vurea value greater than 1.4.
b. If the patient is sensitive to ethylene oxide or the dialysis membrane, a gamma-irradiated
or noncomplement-activating membrane should be used.
c. Compliance with dietary restrictions and phosphate-binding therapy should be encour‐
aged.
d. Epoetin alpha therapy should start at 36- 360 units/kg intravenously or subcutaneously
weekly and be optimized according to hemoglobin and hematocrit values.
e. Topical emollients should be started if the symptoms persist and followed by step therapy
in Figure 1.
Without definitive treatment of the underlying disease, therapy for hemodialysis-related
pruritus is often palliative at best, aiming to minimize the severity of pruritus and to improve
patients' quality of life.
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